Ara-290

ARA-290, also known as cibinetide or innate repair receptor agonist, is a neuroprotection research peptide that has garnered significant attention in laboratory studies for its unique mechanism of action. This compound selectively binds to the innate repair receptor (IRR), which is a heterodimer composed of the EPO receptor and beta common receptor (CD131). What distinguishes ARA-290 from erythropoietin (EPO) is its selective receptor binding profile. Whilst EPO activates the classical homodimeric EPO receptor responsible for erythropoiesis, ARA-290 specifically targets the IRR without stimulating red blood cell production. This selective activation makes it particularly valuable for neuroprotection research models. In research studies, IRR activation by ARA-290 triggers multiple beneficial pathways including anti-inflammatory responses through IL-10 upregulation and NF-kB suppression, anti-apoptotic mechanisms, and tissue repair processes. These effects have been observed across various cell types including neurons, endothelial cells, and immune cells in laboratory investigations. Phase 2 clinical trials have examined ARA-290 for sarcoidosis-related neuropathy, demonstrating improvements in corneal nerve fibre density and neuropathic pain parameters. Research has also explored its potential in diabetic neuropathy models, with studies indicating its effectiveness in treating small fibre neuropathy conditions. ARA-290 represents one of the more clinically advanced research peptides in the neuroprotection field, with evidence grade B supporting its research applications. Laboratory studies continue to investigate its tissue repair properties across multiple organ systems, making it a compound of considerable interest for researchers studying neuroprotective mechanisms and innate repair pathways.